Cargando…

Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation

BACKGROUND: Heparanase, endoglycosidase that cleaves heparan sulfate side chains of heparan sulfate proteoglycans, plays important roles in cancer metastasis, angiogenesis and inflammation. DESIGN AND METHODS: Applying a mouse model of bone marrow transplantation and transgenic mice over-expressing...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitan, Menachem, Weiss, Lola, Zeira, Michael, Zcharia, Eyal, Slavin, Shimon, Nagler, Arnon, Vlodavsky, Israel
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855345/
https://www.ncbi.nlm.nih.gov/pubmed/20419162
http://dx.doi.org/10.1371/journal.pone.0010135
_version_ 1782180173101137920
author Bitan, Menachem
Weiss, Lola
Zeira, Michael
Zcharia, Eyal
Slavin, Shimon
Nagler, Arnon
Vlodavsky, Israel
author_facet Bitan, Menachem
Weiss, Lola
Zeira, Michael
Zcharia, Eyal
Slavin, Shimon
Nagler, Arnon
Vlodavsky, Israel
author_sort Bitan, Menachem
collection PubMed
description BACKGROUND: Heparanase, endoglycosidase that cleaves heparan sulfate side chains of heparan sulfate proteoglycans, plays important roles in cancer metastasis, angiogenesis and inflammation. DESIGN AND METHODS: Applying a mouse model of bone marrow transplantation and transgenic mice over-expressing heparanase, we evaluated the effect of heparanase on the engraftment process and the development of graft-versus-host disease. RESULTS: Analysis of F1 mice undergoing allogeneic bone marrow transplantation from C57BL/6 mice demonstrated a better and faster engraftment in mice receiving cells from donors that were pretreated with heparanase. Moreover, heparanase treated recipient F1 mice showed only a mild appearance of graft-versus-host disease and died 27 days post transplantation while control mice rapidly developed signs of graft-versus-host disease (i.e., weight loss, hair loss, diarrhea) and died after 12 days, indicating a protective effect of heparanase against graft-versus-host disease. Similarly, we applied transgenic mice over-expressing heparanase in most tissues as the recipients of BMT from C57BL/6 mice. Monitoring clinical parameters of graft-versus-host disease, the transgenic mice showed 100% survival on day 40 post transplantation, compared to only 50% survival on day 14, in the control group. In vitro and in vivo studies revealed that heparanase inhibited T cell function and activation through modulation of their cytokine repertoire, indicated by a marked increase in the levels of Interleukin-4, Interleukin-6 and Interleukin-10, and a parallel decrease in Interleukin-12, tumor necrosis factor-alfa and interferon-gamma. Using point mutated inactive enzyme, we found that the shift in cytokine profile was independent of heparanase enzymatic activity. CONCLUSIONS: Our results indicate a significant role of heparanase in bone marrow transplantation biology, facilitating engraftment and suppressing graft-versus-host disease, apparently through an effect on T cell activation and cytokine production pattern.
format Text
id pubmed-2855345
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28553452010-04-23 Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation Bitan, Menachem Weiss, Lola Zeira, Michael Zcharia, Eyal Slavin, Shimon Nagler, Arnon Vlodavsky, Israel PLoS One Research Article BACKGROUND: Heparanase, endoglycosidase that cleaves heparan sulfate side chains of heparan sulfate proteoglycans, plays important roles in cancer metastasis, angiogenesis and inflammation. DESIGN AND METHODS: Applying a mouse model of bone marrow transplantation and transgenic mice over-expressing heparanase, we evaluated the effect of heparanase on the engraftment process and the development of graft-versus-host disease. RESULTS: Analysis of F1 mice undergoing allogeneic bone marrow transplantation from C57BL/6 mice demonstrated a better and faster engraftment in mice receiving cells from donors that were pretreated with heparanase. Moreover, heparanase treated recipient F1 mice showed only a mild appearance of graft-versus-host disease and died 27 days post transplantation while control mice rapidly developed signs of graft-versus-host disease (i.e., weight loss, hair loss, diarrhea) and died after 12 days, indicating a protective effect of heparanase against graft-versus-host disease. Similarly, we applied transgenic mice over-expressing heparanase in most tissues as the recipients of BMT from C57BL/6 mice. Monitoring clinical parameters of graft-versus-host disease, the transgenic mice showed 100% survival on day 40 post transplantation, compared to only 50% survival on day 14, in the control group. In vitro and in vivo studies revealed that heparanase inhibited T cell function and activation through modulation of their cytokine repertoire, indicated by a marked increase in the levels of Interleukin-4, Interleukin-6 and Interleukin-10, and a parallel decrease in Interleukin-12, tumor necrosis factor-alfa and interferon-gamma. Using point mutated inactive enzyme, we found that the shift in cytokine profile was independent of heparanase enzymatic activity. CONCLUSIONS: Our results indicate a significant role of heparanase in bone marrow transplantation biology, facilitating engraftment and suppressing graft-versus-host disease, apparently through an effect on T cell activation and cytokine production pattern. Public Library of Science 2010-04-15 /pmc/articles/PMC2855345/ /pubmed/20419162 http://dx.doi.org/10.1371/journal.pone.0010135 Text en Bitan et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bitan, Menachem
Weiss, Lola
Zeira, Michael
Zcharia, Eyal
Slavin, Shimon
Nagler, Arnon
Vlodavsky, Israel
Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation
title Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation
title_full Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation
title_fullStr Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation
title_full_unstemmed Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation
title_short Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation
title_sort heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855345/
https://www.ncbi.nlm.nih.gov/pubmed/20419162
http://dx.doi.org/10.1371/journal.pone.0010135
work_keys_str_mv AT bitanmenachem heparanasepromotesengraftmentandpreventsgraftversushostdiseaseinstemcelltransplantation
AT weisslola heparanasepromotesengraftmentandpreventsgraftversushostdiseaseinstemcelltransplantation
AT zeiramichael heparanasepromotesengraftmentandpreventsgraftversushostdiseaseinstemcelltransplantation
AT zchariaeyal heparanasepromotesengraftmentandpreventsgraftversushostdiseaseinstemcelltransplantation
AT slavinshimon heparanasepromotesengraftmentandpreventsgraftversushostdiseaseinstemcelltransplantation
AT naglerarnon heparanasepromotesengraftmentandpreventsgraftversushostdiseaseinstemcelltransplantation
AT vlodavskyisrael heparanasepromotesengraftmentandpreventsgraftversushostdiseaseinstemcelltransplantation